FutureGen Industries Provides Investment Performance Update and Shares Realized Gains Psychedelics Investing
Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia Psychedelics Investing
Compass Pathways to attend TD Cowen 46th Annual Healthcare Conference in Boston, MA from March 2-4, 2026 Psychedelics Investing
Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression Psychedelics Investing
Optimi Health Reports First MDMA-Assisted Treatments of 2026 are Underway Across an Expanded Network of Australian Clinics Psychedelics Investing
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Psychedelics Investing
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Psychedelics Investing
